News
IFRX
2.120
+0.47%
0.010
Weekly Report: what happened at IFRX last week (0629-0703)?
Weekly Report · 1d ago
Strong Buy at under $10: The highest Quant-rated bargain stocks right now
Seeking Alpha · 4d ago
InflaRx Moves to Broaden AAV Strategy in Europe After EMA Setback for Tavneos
TipRanks · 06/30 20:28
InflaRx (IFRX) Gets a Buy from Oppenheimer
TipRanks · 06/30 12:15
InflaRx Mulls Feasibility For AAV In Europe
Benzinga · 06/30 11:37
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
Barchart · 06/30 06:30
Weekly Report: what happened at IFRX last week (0622-0626)?
Weekly Report · 06/29 09:10
Strength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength?
NASDAQ · 06/26 09:16
Weekly Report: what happened at IFRX last week (0615-0619)?
Weekly Report · 06/22 09:12
Weekly Report: what happened at IFRX last week (0608-0612)?
Weekly Report · 06/15 09:11
Palisade Bio adds Robert Baltera, Jordan Zwick to board of directors
PUBT · 06/11 12:45
Weekly Report: what happened at IFRX last week (0601-0605)?
Weekly Report · 06/08 09:11
Weekly Report: what happened at IFRX last week (0525-0529)?
Weekly Report · 06/01 09:12
Weekly Report: what happened at IFRX last week (0518-0522)?
Weekly Report · 05/25 09:12
Weekly Report: what happened at IFRX last week (0511-0515)?
Weekly Report · 05/18 09:12
InflaRx Raised to Strong Buy From Outperform by Raymond James
Dow Jones · 05/13 18:03
InflaRx Price Target Raised to $9.00/Share From $7.00 by Raymond James
Dow Jones · 05/13 18:03
Raymond James Upgrades InflaRx to Strong Buy, Raises Price Target to $9
Benzinga · 05/13 17:53
InflaRx upgraded to Strong Buy from Outperform at Raymond James
TipRanks · 05/13 12:32
InflaRx price target raised to $8 from $6 at H.C. Wainwright
TipRanks · 05/11 18:30
More
Webull provides a variety of real-time IFRX stock news. You can receive the latest news about Inflarx through multiple platforms. This information may help you make smarter investment decisions.
About IFRX
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.